Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study

Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. Patients with metastatic or recur...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2004-01, Vol.22 (1), p.91-97
Main Authors: Urba, Susan G, Chansky, Kari, VanVeldhuizen, Peter J, Pluenneke, Robert E, Benedetti, Jacqueline K, Macdonald, John S, Abbruzzese, James L
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adenocarcinoma - secondary
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - secondary
Chemotherapy
Cisplatin - administration & dosage
Creatinine
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Disease
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Female
Granulocytes
Humans
Kinases
Male
Medical prognosis
Metastasis
Middle Aged
Neoplasm Recurrence, Local
Oncology
Patients
Radiation
Response rates
Survival Rate
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. This regimen is tolerable palliative option for patients with metastatic esophageal cancer.
ISSN:0167-6997
1573-0646
DOI:10.1023/B:DRUG.0000006179.20974.af